

AMENDMENTS TO THE CLAIMS:

Kindly cancel claims 13-20, without prejudice, amend claims 3 and 5, and add new claims 24-32, as shown below.

This listing of claims will replace all prior versions and listings of claims in the Application:

Claims 1-2 (cancelled)

Claim 3 (currently amended): A pharmaceutical delivery package according to claim [[24]]21, wherein said ingestible membrane comprises an alkali-dissolvable or acid-dissolvable material.

Claim 4 (cancelled)

Claim 5 (currently amended): A pharmaceutical delivery package consisting of fixed unit dose quantities of two or more different powdered pharmaceutical ingredients, wherein said pharmaceutical ingredients are selected from the group consisting of a mixture of Ketoconazole and testosterone, a mixture of Valacylovir and Cimetidine, a mixture of Valacylovir and Probenecid, a mixture of Valacylovir, Cimetidine and Probenecid, a mixture of Enalapril and a beta-adrenergic blocking agent, methyldopa, nitrate, a calcium blocking agent, hydrazinc, Prazosin or Digoxin, a mixture of Omeprazole and B12, a mixture of Tamoxifen and a diuretic, a mixture of Isotretinoin and an oral contraceptive, and a mixture of Metformin HCl and Sulfonylurea, separated from one another on an ingestible membrane which forms a single delivery package, wherein said ingestible membrane has selected permeability porosity to fluids for controlled release of said powdered pharmaceutical ingredients at two or more different selected sites within the stomach or intestines of a patient's alimentary canal, further comprising a mucosal adhesive layer on an outer surface of the membrane.

Claim 6 (previously presented): A pharmaceutical delivery package according to claim 5, wherein the adhesive is acid or alkaline activatable.

Claim 7 (original): A pharmaceutical delivery package according to claim 5, and further comprising an alkali or acid dissolvable membrane covering the adhesive.

Claim 8 (previously presented): A pharmaceutical delivery package according to claim 5, wherein said membrane comprises a material which expands upon contact with acid or alkaline in the alimentary canal, whereby to become more porous.

Claim 9 (previously presented): A pharmaceutical delivery package according to claim 5, wherein said membrane is formed into a tablet or capsule.

Claim 10 (previously presented): A pharmaceutical delivery package according to claim 5, wherein said powdered pharmaceutical ingredients are segregated from one another in a compartmentalized capsule.

Claim 11 (previously presented): A pharmaceutical delivery package according to claim 5, wherein said powdered pharmaceutical ingredients are segregated from one another in a tablet.

Claim 12 (previously presented): A pharmaceutical delivery package according to claim 5, wherein said powdered pharmaceutical ingredients are encapsulated within inert coatings.

Claim 13-20 (cancelled).

Claim 21 (previously presented): A controlled release pharmaceutical delivery package consisting of fixed unit dose quantities of two or more different powdered pharmaceutical ingredients combined in a single delivery package, wherein said delivery package comprises an ingestible membrane, and said two or more different powdered pharmaceutical ingredients comprise combinations of active pharmaceutical ingredients selected from the group consisting of (a) a mixture of Ketoconazole and testosterone, (b) a mixture of Valacyclovir and one or both

of Cimetidine and Probenecid, (c) a mixture of Enalapril and a beta-adrenergic blocking agent, methyldopa, nitrate, a calcium blocking agent, hydrazinc, Prazosin or Digoxin, (d) a mixture of Omeprazole and B12, (e) a mixture of Tamoxifen and a diuretic, (f) a mixture of Isotretinoin and an oral contraceptive, and (g) a mixture of Metformin HCl and Sulfonylurea, further comprising an adhesive on an outer surface of the membrane.

Claim 22 (previously presented): A pharmaceutical delivery package consisting of fixed unit dose quantities of two or more different powdered pharmaceutical ingredients separated from one another on an ingestible membrane which forms a single delivery package, wherein said ingestible membrane has selected permeability porosity to fluids for controlled release of said powdered pharmaceutical ingredients at a selected site or sites within a patient's alimentary canal,

wherein said two or more powdered pharmaceutical ingredients are deposited on said membrane, separated from one another by one or more barriers or membranes, and wherein said two or more powdered pharmaceutical ingredients are selected from the group consisting of (a) a mixture of Ketoconazole and testosterone, (b) a mixture of Valacylovir and one or both of Cimetidine and Probenecid, (c) a mixture of Enalapril and a beta-adrenergic blocking agent, methyldopa, nitrate, a calcium blocking agent, hydrazinc, Prazosin or Digoxin, (d) a mixture of Omeprazole and B12, (e) a mixture of Tamoxifen and a diuretic, (f) a mixture of Isotretinoin and an oral contraceptive, and (g) a mixture of Metformin HCl and Sulfonylurea.

Claim 23 (previously presented): A pharmaceutical delivery package consisting of fixed unit dose quantities of two or more different powdered pharmaceutical ingredients separated from one another on an ingestible membrane which forms a single delivery package, wherein said ingestible membrane has selected permeability porosity to fluids for controlled release of said

powdered pharmaceutical ingredients at two or more different selected sites within a patient's alimentary canal,

wherein said two or more powdered pharmaceutical ingredients are deposited on said membrane, separated from one another by one or more barriers or membranes, and wherein said two or more powdered pharmaceutical ingredients are selected from the group consisting of Ketoconazole and testosterone; Valacylovir and one or both of Cimetidine and Probenecid; Enalapril and a beta-adrenergic blocking agent, methyldopa, nitrate, a calcium blocking agent, hydrazinc, Prazosin or Digoxin; Omeprazole and B12; Tamoxifen and a diuretic; Isotretinoin and an oral contraceptive; and Metformin HC1 and Sulfonylurea.

Claim 24 (new): A pharmaceutical delivery package according to claim 22, wherein said ingestible membrane comprises an alkali-dissolvable or acid-dissolvable material.

Claim 25 (new): A pharmaceutical delivery package according to claim 23, wherein said ingestible membrane comprises an alkali-dissolvable or acid-dissolvable material.

Claim 26 (new): A pharmaceutical delivery package according to claim 5, wherein said ingestible membrane comprises an alkali-dissolvable or acid-dissolvable material.

Claim 27 (new): A pharmaceutical delivery package according to claim 21, wherein said membrane is formed into a tablet or capsule.

Claim 28 (new): A pharmaceutical delivery package according to claim 21, wherein said powdered pharmaceutical ingredients are segregated from one another in a compartmentalized capsule.

Claim 29 (previously presented): A pharmaceutical delivery package according to claim 22, wherein said membrane is formed into a tablet or capsule.

HAYES SOLOWAY P.C.
130 W. CUSHING STREET
TUCSON, AZ 85701
TEL. 520.882.7623
FAX. 520.882.7643

175 CANAL STREET
MANCHESTER, NH 03101
TEL. 603.668.1400
FAX. 603.668.8567

Claim 30 (new): A pharmaceutical delivery package according to claim 22, wherein said powdered pharmaceutical ingredients are segregated from one another in a compartmentalized capsule.

Claim 31 (previously presented): A pharmaceutical delivery package according to claim 23, wherein said membrane is formed into a tablet or capsule.

Claim 32 (new): A pharmaceutical delivery package according to claim 23, wherein said powdered pharmaceutical ingredients are segregated from one another in a compartmentalized capsule.

HAYES SOLOWAY P.C.
130 W. CUSHING STREET
TUCSON, AZ 85701
TEL. 520.882.7623
FAX. 520.882.7643

—
175 CANAL STREET
MANCHESTER, NH 03101
TEL. 603.668.1400
FAX. 603.668.8567